Insmed to Host Second Quarter 2017 Financial Results Conference Call on Thursday, August 3, 2017
Shareholders and other interested parties may participate in the conference call by dialing (844) 707-0669 (domestic) or (703) 639-1223 (international) and referencing conference ID number 53207980. The call will also be webcast live on the internet on the company's website at www.insmed.com.
A replay of the conference call will be accessible approximately two hours after its completion through
Insmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. The Company is advancing a global phase 3 clinical study of amikacin liposome inhalation suspension (ALIS) for adult patients with treatment refractory NTM lung disease caused by MAC, a rare and often chronic
infection that is capable of causing irreversible lung damage and can be fatal. There are currently no approved inhaled products specifically indicated for the treatment of refractory NTM lung infections caused by MAC in the United States or European Union (EU).
"Insmed" is the Company's trademark. All other trademarks, trade names or service marks appearing in this press release are the property of their respective owners.
Blaine DavisVP, Head of Investor Relations 908-947-2841 Blaine.Davis@insmed.com
News Provided by Acquire Media